- Agilent (A) expects FQ3 revenue of $1.74B-$1.76B and EPS of $0.72-$0.74 vs. a consensus of $1.74B and $0.79. FY14 (ends in Oct) guidance is for revenue of $6.9B-$7.1B and EPS of $2.96-$3.16 vs. a consensus of $6.98B and $3.08.
- Orders rose 7% Y/Y in FQ2, better than FQ2's 2% decline and favorable to flat revenue growth. Life sciences/diagnostics orders +6% to $598M, chemical analysis +4% to $432M, electronic measurement (due for a spinoff) +12% to $782M. Book-to-bill was 1.05.
- Gross margin was 51.9%, up slightly Y/Y but down 70 bps Q/Q. R&D spend fell 3% Y/Y to $176M, SG&A spend rose 3% to $513M.
- A -0.5% AH. FQ2 results, PR.
From other sites
at CNBC.com (Nov 24, 2014)
at CNBC.com (Nov 18, 2014)
at CNBC.com (Nov 17, 2014)
at CNBC.com (Nov 14, 2014)
at CNBC.com (Nov 9, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs